PRINCETON, N.J., May 30, 2017 /PRNewswire/ -- Taiho Oncology, Inc. announces the sponsorship of the CHOICE Registry, the first-ever observational research initiative designed to provide critical insights into the management of metastatic colorectal cancer (mCRC). The CHOICE RegistryTM (A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer) will describe real-world treatment patterns and physician, patient, and caregiver-reported outcomes associated with patients who have progressed beyond second line metastatic colorectal cancer.
"What's unique about the CHOICE Registry is that it does not focus on any particular product or treatment regimen," states Eric Benn, President and Chief Executive Officer of Taiho Oncology. "Physicians will provide treatment to patients as per their standard of care. Reflecting the diversity of patients and treatment modalities, approximately 1,000 patients will be enrolled by community-based and academic centers across the U.S. and appropriately followed up to determine patient outcomes."
Chairperson of the CHOICE Registry Scientific Advisory Panel, Mark Kozloff, M.D. (Medical Director of Ingalls Cancer Care, Harvey, Illinois, Chair of Ingalls' Cancer Clinical Trials Sub-Committee, and Clinical Associate Professor of the University of Chicago Hospitals) stated, "Practitioners, patients, payers, and policymakers are increasingly looking to observational studies and patient registries to better understand the impact of evolving treatment options in 'real world' actual practice settings. Translating results from Randomized Controlled Trials of new agents into general clinical practice can be challenging, as RCT results are based on selected patients who may not fully represent the general patient population treated in the community."
Taiho Oncology, Inc. has selected Continuum Clinical of Northbrook, IL to support the design and implementation of the CHOICE Registry. Jeffrey Trotter, President of Continuum states, "The CHOICE Registry will seek to provide a better understanding about the progression of metastatic CRC and the approaches currently employed in 'real world' clinical settings to manage post-second line mCRC treatment. Also, in consideration of other important non-clinical parameters, the CHOICE Registry will examine economic and patient-reported outcomes to highlight the impact of various treatment options in terms of resource utilization, cost, and patient preference, satisfaction with treatment, quality-of-life and caregiver burden."
About Colorectal Cancer
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and females in the United States (1,2). The American Cancer Society estimates that 135,430 people will be diagnosed with colorectal cancer, and that 50,260 people will die from the disease in 2017 (1, 2). Approximately 1 in 22 men and 1 in 24 women will be diagnosed with cancer of the colon or rectum in their lifetime (1).
About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established world class clinical development and commercial organizations that work urgently to develop and market innovative cancer treatments in the U.S. Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It's our work; it's our passion; it's our legacy.
For more information about Taiho Oncology, Inc. please visit: http://www.taihooncology.com.
About Continuum Clinical, LLC
A subsidiary of Blue Chip Worldwide, Continuum was formed in 2014 with roots extending back over thirty years. Continuum Clinical brings together a unique blend of world-class experience in key disciplines, including the design and implementation of "real world" evidence initiatives, health economics, epidemiology, observational studies and patient registries, and patient recruitment for clinical trials.
1. Cancer Facts & Figures 2017. American Cancer Society.
2. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193.
GCI Health on behalf of Taiho Oncology
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/innovative-patient-registry-to-provide-important-insights-into-the-real-world-management-of-metastatic-colorectal-cancer-300464075.html
SOURCE Taiho Oncology, Inc.